LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
S. Y. Martsevich (2007)
Publisher: Stolichnaya Izdatelskaya Kompaniya
Journal: Racionalʹnaâ Farmakoterapiâ v Kardiologii
Languages: English
Types: Article
Subjects: RC666-701, артериальная гипертония, ишемическая болезнь сердца, антагонисты кальция, Diseases of the circulatory (Cardiovascular) system, ischemic heart disease, дигидропиридины, сердечно-сосудистые осложнения, calcium antagonists, cardiovascular complications, arterial hypertension, RM1-950, Therapeutics. Pharmacology, dihydropyridines

The classification of calcium antagonists is presented. There were considered the results of large randomized trials, which were devoted to study of influence of dihydropyridine calcium antagonists on the risk of cardiovascular complications. The place of dihydropyridine calcium antagonists in modern recommendations on treatment of arterial hypertension and ischemic heart disease is defined. The clinical importance of differences between various presentations of dihy-dropyridine calcium antagonists is stressed.

  • No references.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article

Collected from